For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Tafamidis and Tafamidis meglumine represents a significant change. These innovative therapies preserve the transthyretin protein, slowing its destructive build-up and alleviating the